HIV/AIDS

  • Read more: The Ban on Federal Funding of Syringes — continued
    Article

    The Ban on Federal Funding of Syringes — continued

    By Scott Burris People arguing that our federal government spends “too much” sound more and more like cynics by Oscar Wilde’s famous definition: knowing the price of everything and the value of nothing. I’m neither for big government nor small government. I’d like government that does important things effectively and efficiently. One very effective and…

  • Read more: Impact of the Sequester on Health Care: By the Numbers
    Article

    Impact of the Sequester on Health Care: By the Numbers

    By: Katie Booth  The looming sequester will have a significant impact on health care, including cuts to Medicare, FDA, CDC, NIH, and Affordable Care Act programs. Budget cuts could slow down the drug approval process, impede the tracking of infectious diseases, and lead to layoffs for hundreds of thousands of workers in the health care…

  • Read more: Dave Purchase and Naloxone, Life Savers
    Article

    Dave Purchase and Naloxone, Life Savers

    By Scott Burris Start with the sad news of the week. Dave Purchase died, aged 73. Dave was the father of needle exchange in the US, which as far as anyone can say started with Dave and a TV tray in disregard of Oregon’s drug paraphernalia law. Dave was a father figure to a whole…

  • Read more: Upcoming, Feb. 6 – Drug Use and HIV: A Tale of Toxic Law
    Article

    Upcoming, Feb. 6 – Drug Use and HIV: A Tale of Toxic Law

    By The Petrie-Flom Center THE NORTHEASTERN PROGRAM ON HEALTH POLICY & LAW PRESENTS: HIV/AIDS Policy Grand Rounds: Drug Use and HIV: A Tale of Toxic Law In the wake of the HIV epidemic, legal and policy tools became critical in combatting the epidemic. The HIV/AIDS Policy Grand Rounds is an interdisciplinary series of workshops designed to…

  • Read more: Film Review: How to Survive a Plague
    Article

    Film Review: How to Survive a Plague

    By Suzanne M. Rivera How to Survive a Plague is a moving chronicle of the onset of the AIDS epidemic as seen through the lens of the activists who mobilized to identify and make available the effective treatments we have today.  Beginning at the start of the epidemic, when little was known about the HIV…

  • Read more: Twitter Round-Up (11/25-12/1)
    Article

    Twitter Round-Up (11/25-12/1)

    By Casey Thomson From policy adoption at the federal level to debate over the health concerns of political figures, this week’s round-up focuses largely on the news for bioethics and health law in the realm of politics. Dan Vorhaus (@genomicslawyer) posted a feature on the history of gene patent litigation and implications for next-generation sequencing technologies.…

  • Read more: Reminder, TODAY – Advances in HIV Prevention: Legal, Clinical, and Public Health Issues
    Article

    Reminder, TODAY – Advances in HIV Prevention: Legal, Clinical, and Public Health Issues

    TODAY! 12-1:30pm Austin Hall, Room 111 Harvard Law School On July 3, 2012, FDA approved OraQuick, the first at-home HIV test available for sale directly to consumers, allowing individuals to self-test and receive confidential results in about 20 minutes. Then on July 16, FDA approved once-daily Truvada, an already-approved HIV therapy, as the first agent approved for…

  • Read more: Upcoming Event – Advances in HIV Prevention: Legal, Clinical, and Public Health Issues
    Article

    Upcoming Event – Advances in HIV Prevention: Legal, Clinical, and Public Health Issues

    Monday, November 5, 2012 12-1:30 pm Austin Hall, Room 111 Harvard Law School On July 3, 2012, FDA approved OraQuick, the first at-home HIV test available for sale directly to consumers, allowing individuals to self-test and receive confidential results in about 20 minutes. Then on July 16, FDA approved once-daily Truvada, an already-approved HIV therapy, as the…